ADAG Adagene ADS (N Shares)

Adagene to Participate in the Jefferies Virtual China Biotech Summit

Adagene to Participate in the Jefferies Virtual China Biotech Summit

SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual China Biotech Summit to be held October 26, 2021.

Details on the presentation include:

Date: Tuesday, October 26, 2021

Presentation Time: 3:00 p.m. Eastern

A live webcast of the presentation will also be accessible in the section of the company’s website at . A webcast replay will be available for at least 30 days.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody™, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: .

Internal Contact:

Ami Knoefler

Adagene

650-739-9952

External Contact:

Bruce Mackle

LifeSci Advisors

646-889-1200



EN
21/10/2021

Underlying

ADAGAdagene ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adagene ADS (N Shares)

 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene to Participate in Two Upcoming Investor Conferences

Adagene to Participate in Two Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held virtually on February 25, 2026 and the Leerink Global Healthcare Conference being held March 8-11, 2026 in M...

February 17, 2026 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Provides Business Update and 2026 Objectives

Adagene Provides Business Update and 2026 Objectives Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027 SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalents of $74.5 million and prov...

January 23, 2026 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pe...

December 16, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces Licensing Agreement with Third Arc Bio for Developme...

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated antigens. Under the terms of the agreement, Third Arc Bio will receive rights to research, develop and...

November 13, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on  Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug...

October 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch